Shang­hai biotech up­start rais­es $50M, bags an­ti­body dis­cov­ery group and ramps up Boston unit

A new Shang­hai-based biotech up­start is tak­ing part of its $50 mil­lion A round to ac­quire an an­ti­body dis­cov­ery out­fit in Rot­ter­dam while blue­print­ing plans …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.